{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resected+Stage&page=4", "query": { "condition": "Resected Stage", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 544, "total_pages": 55, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resected+Stage&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resected+Stage&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T23:58:28.712Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07195695", "title": "Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Zongertinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2026-01-16", "completion_date": "2036-09-02", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 27, "location_summary": "Fresno, California • Glendale, California • Orange, California + 21 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07195695" }, { "nct_id": "NCT04317534", "title": "Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC, Stage I" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Greg Durm, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2020-05-05", "completion_date": "2028-04-08", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 13, "location_summary": "Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04317534" }, { "nct_id": "NCT07276789", "title": "Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "LS301-IT 0.1 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Integro Theranostics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-12-08", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07276789" }, { "nct_id": "NCT02126579", "title": "Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Metastatic Melanoma", "Mucosal Melanoma" ], "interventions": [ { "name": "Peptide Vaccine (LPV7) + Tetanus peptide", "type": "BIOLOGICAL" }, { "name": "PolyICLC", "type": "OTHER" }, { "name": "Resiquimod", "type": "OTHER" }, { "name": "IFA", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-05-01", "completion_date": "2021-05-05", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 2, "location_summary": "Houston, Texas • Charlottesville, Virginia", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02126579" }, { "nct_id": "NCT02010203", "title": "A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "HS-410", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "BCG", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Heat Biologics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2013-12", "completion_date": "2018-04", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 19, "location_summary": "Los Angeles, California • Sherman Oaks, California • Torrance, California + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02010203" }, { "nct_id": "NCT02388906", "title": "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Placebo matching Ipilimumab", "type": "OTHER" }, { "name": "Placebo matching Nivolumab", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 906, "start_date": "2015-03-16", "completion_date": "2024-10-16", "has_results": true, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 35, "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 27 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02388906" }, { "nct_id": "NCT00017160", "title": "Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Adult Soft Tissue Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Stage IVA Adult Soft Tissue Sarcoma", "Stage IIB Adult Soft Tissue Sarcoma", "Stage IIC Adult Soft Tissue Sarcoma" ], "interventions": [ { "name": "doxorubicin", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "biological response modifier therapy", "type": "PROCEDURE" }, { "name": "brachytherapy", "type": "PROCEDURE" }, { "name": "chemotherapy", "type": "PROCEDURE" }, { "name": "colony-stimulating factor therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "cytokine therapy", "type": "PROCEDURE" }, { "name": "intraoperative radiotherapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "PROCEDURE" }, { "name": "surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-27", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 216, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017160" }, { "nct_id": "NCT04066894", "title": "Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Anterior Resection Syndrome", "Malignant Anal Neoplasm", "Malignant Bladder Neoplasm", "Malignant Cervical Neoplasm", "Malignant Ovarian Neoplasm", "Malignant Pelvic Neoplasm", "Malignant Prostate Neoplasm", "Malignant Uterine Neoplasm", "Malignant Vaginal Neoplasm", "Malignant Vulvar Neoplasm", "Rectal Carcinoma" ], "interventions": [ { "name": "Explantation", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sacral Nerve Stimulator", "type": "DEVICE" }, { "name": "Sacral Nerve Stimulator Battery", "type": "DEVICE" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DEVICE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-04-12", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 2, "location_summary": "Houston, Texas • Sugar Land, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04066894" }, { "nct_id": "NCT01892839", "title": "Increasing the Removal of Protein-Bound Solutes During Extended Hours Hemodialysis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "End Stage Renal Failure on Dialysis" ], "interventions": [ { "name": "low dialysate flow, smaller dialyzer", "type": "OTHER" }, { "name": "high dialysate flow, larger dialyzer", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Palo Alto Veterans Institute for Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 24, "start_date": "2013-07", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2015-07-13", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 2, "location_summary": "Redwood City, California • Stanford, California", "locations": [ { "city": "Redwood City", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01892839" }, { "nct_id": "NCT00238277", "title": "Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "chemotherapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 15, "start_date": "2005-02-15", "completion_date": "2007-12-11", "has_results": false, "last_update_posted_date": "2018-06-27", "last_synced_at": "2026-10-21T23:58:28.712Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00238277" } ] }